drugset / Trial / NCT02612298
Efficacy and Safety of Arotinolol Hydrochloride on Morning Blood Pressure and Heart Rate
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to compare the efficacy and safety of Arotinolol Hydrochloride and Metoprolol succinate on morning blood pressure, heart rate and target organ damage in patients with essential hypertension. To provide evidence for hypertension treatment. A group: Arotinolol Hydrochloride, oral, 5-15mg, bid for 12 weeks. B group: Metoprolol succinate sustained-release tablet, oral, 23.75-71.25mg, qd for 12 weeks.
Timeline
- Start
- 2015-08
- Primary completion
- 2018-09-13
- Completion
- 2018-09-13
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Arotinolol | Small molecule | 5 mg | Oral |
| Subject | Arotinolol | Small molecule | 15 mg | Oral |
| Comparator | Metoprolol | Other / unclassified | 23.75 mg | Oral |
| Comparator | Metoprolol | Other / unclassified | 71.25 mg | Oral |